Sintilimab Clinical Trials in Hangzhou, Zhejiang
2 recruitingHangzhou, Zhejiang, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
SintilimabCentral Nervous System LymphomaPirtobrutinib
Zhejiang Cancer Hospital24 enrolled1 locationNCT07416890
Recruiting
Phase 2
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
Esophageal CancerImmunotherapyChemoradiotherapy+2 more
Zhejiang Cancer Hospital191 enrolled1 locationNCT06413342